FIGURE 2 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment

Le résumé fourni par la source

IL21 is induced by anti-PD-1 mAb and is required for the antitumor efficacy of PD-1 blockade immunotherapy. A, Genome tracks of aggregate scATAC-seq data at the Il21 locus, clustered by different treatment conditions. B, Dot plot showing Il21 expression in CD4+ T cells after PD-1 mAb treatment. C, Randomization of mice 5 days after inoculation with MC38 tumors, followed by intraperitoneal injection of drugs. Injections were given every 4 days for a total of four injections. Mouse tumor growth curves are shown in the figure (n = 4–5). D–G, Tumor growth curves of single mice in different groups. Data are presented as mean ± SEM, and two-way ANOVA test was used to compare the statistical differences of tumor growth curves among multiple groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.